201 related articles for article (PubMed ID: 28502925)
1. Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.
Kinoshita Y; Hongo M; Kusano M; Furuhata Y; Miyagishi H; Ikeuchi S;
Intern Med; 2017; 56(10):1131-1139. PubMed ID: 28502925
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
4. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
[TBL] [Abstract][Full Text] [Related]
5. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
Kinoshita Y; Hongo M;
Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
[TBL] [Abstract][Full Text] [Related]
7. Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan.
Hongo M; Miwa H; Kusano M;
J Gastroenterol; 2011 Mar; 46(3):297-304. PubMed ID: 21082202
[TBL] [Abstract][Full Text] [Related]
8. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Haddad I; Kierkus J; Tron E; Ulmer A; Hu P; Sloan S; Silber S; Leitz G
J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):798-807. PubMed ID: 23863328
[TBL] [Abstract][Full Text] [Related]
10. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Fujimoto K; Hongo M;
Intern Med; 2011; 50(3):179-88. PubMed ID: 21297318
[TBL] [Abstract][Full Text] [Related]
12. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
[TBL] [Abstract][Full Text] [Related]
13. Healing erosive esophagitis with a proton pump inhibitor: the more the merrier?
Fass R
Am J Gastroenterol; 2012 Apr; 107(4):531-3. PubMed ID: 22475962
[TBL] [Abstract][Full Text] [Related]
14. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
Nagahara A; Suzuki T; Nagata N; Sugai N; Takeuchi Y; Sakurai K; Miyamoto M; Inoue K; Akiyama J; Mabe K; Konuma I; Kamada T; Haruma K
J Gastroenterol; 2014 Dec; 49(12):1536-47. PubMed ID: 24366288
[TBL] [Abstract][Full Text] [Related]
15. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
16. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
17. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
[TBL] [Abstract][Full Text] [Related]
18. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
[TBL] [Abstract][Full Text] [Related]
19. Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
Miwa H; Takubo K; Shimatani T; Furuta T; Oshima T; Tanaka J; Aida J; Ito M; Kurosawa S; Joh T; Wada T; Habu Y; Watanabe Y; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol Hepatol; 2013 Mar; 28(3):479-87. PubMed ID: 22989221
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]